MedTrace Logo

Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine

NCT06525974 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-07-29

No results posted yet for this study

Summary

Evaluation the possible efficacy and safety of febuxostat in patients with ulcerative colitis treated with mesalamine.

Conditions

Interventions

DRUG

Febuxostat

40mg of Febuxostat once daily

DRUG

Mesalamine

1 g mesalamine three times daily for 3 months.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-01
Primary Completion
2026-09-30
Completion
2026-12-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06525974 on ClinicalTrials.gov